Andrew J. Murphy, EVP Research at REGENERON PHARMACEUTICALS, INC. (REGN), sold 13,309 shares at $668.68 ($8.7M) on 2022-05-17, disclosed to the SEC on 2022-05-18.
Open-market sale of $8.7M REGN by EVP Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $648.31 | 6,457 | $4.2M | 47.9% |
| 2 | $655.40 | 59 | $39K | 0.4% |
| 3 | $656.52 | 58 | $38K | 0.4% |
| 4 | $657.51 | 60 | $39K | 0.5% |
| 5 | $658.56 | 123 | $81K | 0.9% |
| 6 | $658.56 | 123 |
| $81K |
| 0.9% |
| 7 | $660.32 | 77 | $51K | 0.6% |
| 8 | $660.32 | 77 | $51K | 0.6% |
| 9 | $661.46 | 465 | $308K | 3.5% |
| 10 | $661.46 | 465 | $308K | 3.5% |
| 11 | $662.57 | 779 | $516K | 5.9% |
| 12 | $662.57 | 779 | $516K | 5.9% |
| 13 | $663.60 | 472 | $313K | 3.6% |
| 14 | $663.60 | 472 | $313K | 3.6% |
| 15 | $664.32 | 428 | $284K | 3.3% |
| 16 | $664.32 | 428 | $284K | 3.3% |
| 17 | $665.36 | 126 | $84K | 1.0% |
| 18 | $665.36 | 126 | $84K | 1.0% |
| 19 | $666.23 | 352 | $235K | 2.7% |
| 20 | $666.23 | 352 | $235K | 2.7% |
| 21 | $667.49 | 154 | $103K | 1.2% |
| 22 | $667.49 | 154 | $103K | 1.2% |
| 23 | $668.68 | 180 | $120K | 1.4% |
| 24 | $668.68 | 180 | $120K | 1.4% |
| 25 | $669.12 | 153 | $102K | 1.2% |
| 26 | $669.12 | 153 | $102K | 1.2% |
| 27 | $670.49 | 57 | $38K | 0.4% |
| Total | $656.29 avg | 13,309 | $8.7M | 100% |
| Filing → |
| REGN | SELL | 2024-03-15 | $11.0M | — | Filing → |
| REGN | SELL | 2023-12-06 | $10.6M | — | Filing → |
| REGN | SELL | 2023-11-15 | $10.3M | — | Filing → |